A company with roughly 250 employees sells its product in more than 160 countries. For boards, that is more than an interesting business story. It challenges a basic assumption about what global growth requires.
Boards often treat international expansion as an organizational decision. Entering more markets is expected to require more infrastructure, more people, more capital and greater operating complexity. That assumption is often correct, but not always. My latest paper argues that some products can achieve global reach without creating a multinational organization to support it.
The difference is how the product pays for distance. Coca-Cola ships concentrate and adds water locally, requiring bottling plants, distribution systems and people throughout the world. Wine ships whole and covers freight through premium pricing. Tabasco follows a third route: dosage.
A serving of Tabasco is only a few drops. One small bottle therefore contains hundreds of servings, making the freight cost per serving almost negligible. The product is also shelf-stable and occupies a valuable position on restaurant tables that has been reinforced through brand, habit and more than 150 years of incumbency.
This creates an important governance implication. Boards should not assume that geographic reach and organizational scale must grow together. They should ask which capabilities genuinely need to sit inside the company and which can be supplied by the product, distributors and networks the company does not own.
The reverse question is equally important. A small global workforce may reflect an unusually efficient business model, but it can also create concentrated risks. Boards must understand where knowledge, production, suppliers and decision-making reside, and whether the apparent simplicity of the organization hides critical dependencies.
The organization chart may not explain the company’s reach. The product architecture may explain it first.
For boards overseeing international growth, the question is not simply, “Where should we expand?” It is, “What must we build to get there, and what does the product allow us not to build?”
Read my full article here: "Three Drops: How Dosage, Not Scale, Buys Global Reach"